Nuclear-cytoplasmic transport is a therapeutic target in myelofibrosis.

CONCLUSIONS: Our data implicate NCT as a potential therapeutic target in MF and provide a rationale for clinical evaluation in ruxolitinib exposed MF patients.
PMID: 30563936 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - December 18, 2018 Category: Cancer & Oncology Authors: Yan D, Pomicter AD, Tantravahi S, Mason CC, Senina AV, Ahmann JM, Wang Q, Than H, Patel AB, Heaton W, Eiring AM, Clair PM, Gantz KC, Redwine HM, Swierczek SI, Halverson BJ, Baloglu E, Shacham S, Khorashad JS, Kelley TW, Salama ME, Miles RR, Boucher KM, Pr Tags: Clin Cancer Res Source Type: research